RMD

ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2008

Business Context and Reporting Period

Company: ResMed Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended June 30, 2008
Business Overview: ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates as a single segment, selling airflow generators, mask systems, and diagnostic products in over 70 countries. Key markets include North America (49% of revenue) and Europe (43% of revenue).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 17% to $835.4 million, driven by a 13% increase in flow generator sales and a 21% increase in mask/accessory sales. Favorable foreign currency movements contributed approximately $42.7 million to revenue.
• Profitability Surge: Net income increased 66% to $110.3 million. This significant improvement is largely attributable to the absence of the $59.7 million voluntary product recall charge recognized in fiscal 2007. Excluding recall expenses, diluted EPS grew 4% year-over-year.
• Margin Expansion: Gross margin improved to 59% from 54%. While the prior year was depressed by the recall charge, the current year also faced margin pressure from a stronger Australian dollar and reduced average selling prices, partially offset by supply chain efficiencies.
• Share Repurchases: The company repurchased 2.57 million shares for $99.5 million in fiscal 2008, compared to only 50,000 shares in fiscal 2007.

Guidance, Outlook, Risks, and Unusual Items

• Product Recall: A voluntary recall of approximately 300,000 S8 flow generators initiated in April 2007 continued into fiscal 2008. An additional charge of $3.1 million was recognized in 2008 due to higher return rates and consulting fees. The remaining accrual at year-end was $1.0 million.
• Restructuring: The company incurred $2.4 million in restructuring expenses related to streamlining European management and closing regional offices.
• Investment Liquidity: The company holds $4.6 million in auction rate securities that experienced failed auctions due to global credit market conditions. These were reclassified to non-current assets, though management does not anticipate an impact on operations.
• Outlook: Management expects SG&A expenses to remain in the 32-34% range and R&D expenses at approximately 7% of revenue. Growth is expected to be driven by new product introductions (e.g., S8 Series II, VPAP Auto) and increased awareness of SDB links to cardiovascular disease and diabetes.
• Risks: Key risks include foreign currency fluctuations, third-party reimbursement changes (particularly Medicare competitive bidding), regulatory compliance (FDA), and competition from larger industry consolidations.

Investor Verification Checklist

• Recall Costs: Verify if the remaining $1.0 million accrual for the S8 recall is sufficient or if further charges are anticipated.
• Currency Impact: Assess the sensitivity of future margins to the Australian dollar, given significant manufacturing costs are denominated in AUD while reporting is in USD.
• Auction Rate Securities: Monitor the liquidity status of the $4.6 million investment in auction rate securities and potential write-downs if markets do not improve.
• Reimbursement Policy: Track developments in U.S. Medicare competitive bidding for Durable Medical Equipment (DME) and its potential impact on pricing power.
• German Tax Audit: Review the status of the ongoing German tax audit for years 1996-1998, which could result in material tax adjustments.